Get the Stockscreener App
39.21
4.69%
-1.93
Sionna Therapeutics Inc stock is traded at $39.21, with a volume of 304.23K.
It is down -4.69% in the last 24 hours and up +0.51% over the past month.
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
See More
Previous Close:
$41.14
Open:
$41.46
24h Volume:
304.23K
Relative Volume:
1.00
Market Cap:
$1.75B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-10.27%
1M Performance:
+0.51%
6M Performance:
+87.88%
1Y Performance:
+0.00%
1-Day Range:
$38.93
$41.56
1-Week Range:
$38.93
$45.00
52-Week Range:
$7.255
$45.00
Sionna Therapeutics Inc Stock (SION) Company Profile
Name
Sionna Therapeutics Inc
Sector
Industry
Phone
617-819-2020
Address
21 HICKORY DRIVE, SUITE 500, WALTHAM
Compare SION with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
39.21 | 1.84B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-01-25 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Sep-03-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Mar-04-25 | Initiated | Guggenheim | Buy |
| Mar-04-25 | Initiated | Stifel | Buy |
| Mar-04-25 | Initiated | TD Cowen | Buy |
View All
Sionna Therapeutics Inc Stock (SION) Latest News
Sionna Therapeutics Insider Sold Shares Worth $1,486,010, According to a Recent SEC Filing - marketscreener.com
Sionna Therapeutics (NASDAQ:SION) Director Peter Thompson Sells 33,356 Shares - Defense World
Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells 33,356 Shares of Stock - MarketBeat
OrbiMed Advisors sells Sionna Therapeutics [SION] shares for $1.48m By Investing.com - Investing.com Nigeria
OrbiMed Advisors sells Sionna Therapeutics [SION] shares for $1.48m - Investing.com
Sionna Therapeutics (NASDAQ:SION) Sets New 12-Month HighWhat's Next? - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Broadens Clinical Research Scope - Kalkine Media
Sionna Therapeutics: NBD1-Targeted CFTR Stabilization Strategy Positions Pipeline for Best-in-Class Efficacy and Blockbuster Upside in Cystic Fibrosis - TipRanks
FY2025 Earnings Estimate for SION Issued By Lifesci Capital - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Now Covered by Analysts at Lifesci Capital - Defense World
LifeSci Capital Initiates Coverage of Sionna Therapeutics (SION) with Outperform Recommendation - Nasdaq
Sionna Therapeutics (NASDAQ:SION) Coverage Initiated by Analysts at Lifesci Capital - MarketBeat
LifeSci Capital Initiates Coverage on Sionna Therapeutics With Outperform Rating, $60 Price Target - marketscreener.com
Sionna Therapeutics (NASDAQ:SION) Director Sells $40,050.00 in Stock - Defense World
Sionna Therapeutics, Inc.(NasdaqGM:SION) added to S&P Biotechnology Select Industry Index - marketscreener.com
Sionna Therapeutics, Inc.(NasdaqGM: SION) added to NASDAQ Biotechnology Index - marketscreener.com
Sionna Therapeutics (NASDAQ:SION) Reaches New 1-Year High – Still a Buy? - Defense World
Peter Thompson Sells 900 Shares of Sionna Therapeutics (NASDAQ:SION) Stock - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Director Sells $38,928.75 in Stock - MarketBeat
Shareholder OrbiMed Advisors LLC Sells 1,875 ($83.4K) Of Sionna Therapeutics Inc [SION] - TradingView — Track All Markets
Sionna Therapeutics (NASDAQ:SION) Sets New 1-Year HighHere's What Happened - MarketBeat
How Sionna Therapeutics Inc. stock reacts to oil pricesTrade Entry Summary & Short-Term Trading Alerts - Улправда
Sionna Therapeutics, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Sionna Therapeutics, Inc. Rings the Closing Bell - Nasdaq
Braidwell LP Invests $18.77 Million in Sionna Therapeutics, Inc. $SION - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Upgraded at Wall Street Zen - MarketBeat
Sionna Therapeutics (SION) Stock Analysis Report | Financials & Insights - Benzinga
Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Sionna Therapeutics chief legal officer sells $415,330 in stock By Investing.com - Investing.com Canada
Sionna Therapeutics chief legal officer sells $415,330 in stock - Investing.com India
Sionna Therapeutics Insider Sold Shares Worth $415,330, According to a Recent SEC Filing - marketscreener.com
Officer Fitzpatrick Sells 10,250 ($415.3K) Of Sionna Therapeutics Inc [SION] - TradingView — Track All Markets
Bosun Asset Management LLC Invests $295,000 in Sionna Therapeutics, Inc. $SION - Defense World
Officer Fitzpatrick Files To Sell 10,250 Of Sionna Therapeutics Inc [SION] - TradingView
Sionna Therapeutics, Inc. $SION Shares Acquired by Prudential Financial Inc. - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Shares Up 11.4%What's Next? - MarketBeat
Sionna Therapeutics Valuation Topping $2 Billion Is 'Too Optimistic', RBC Says - marketscreener.com
Transcript : Sionna Therapeutics, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-04-2025 09 - marketscreener.com
Why Sionna Therapeutics Inc. stock remains resilient2025 Short Interest & Long-Term Growth Portfolio Plans - Newser
Will Sionna Therapeutics Inc. stock gain from government policies - Newser
Sionna Therapeutics, Inc. $SION Shares Purchased by JPMorgan Chase & Co. - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Shares Gap DownHere's What Happened - MarketBeat
Views of Wall Street’s Leading Experts on Sionna Therapeutics Inc - Setenews
Royal Bank Of Canada Reiterates "Underperform" Rating for Sionna Therapeutics (NASDAQ:SION) - MarketBeat
Is Sionna Therapeutics Inc. stock affected by interest rate hikesGold Moves & Precise Entry and Exit Recommendations - Newser
Sionna Therapeutics Shares Lower After RBC Downgrade - marketscreener.com
Sionna Therapeutics stock tumbles after RBC downgrade By Investing.com - Investing.com Canada
SION Downgraded by RBC Capital: Today's Analyst Rating | SION St - GuruFocus
Sionna Therapeutics Inc Stock (SION) Financials Data
There is no financial data for Sionna Therapeutics Inc (SION). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Sionna Therapeutics Inc Stock (SION) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thompson Peter A. | Director |
Dec 24 '25 |
Sale |
44.55 |
33,356 |
1,486,010 |
3,561,655 |
| ORBIMED ADVISORS LLC | Director |
Dec 17 '25 |
Sale |
44.50 |
900 |
40,050 |
3,595,986 |
| ORBIMED ADVISORS LLC | Director |
Dec 19 '25 |
Sale |
44.49 |
875 |
38,929 |
3,595,011 |
| ORBIMED ADVISORS LLC | Director |
Dec 18 '25 |
Sale |
44.49 |
100 |
4,449 |
3,595,886 |
| Thompson Peter A. | Director |
Dec 17 '25 |
Sale |
44.50 |
900 |
40,050 |
3,595,986 |
| Thompson Peter A. | Director |
Dec 19 '25 |
Sale |
44.49 |
875 |
38,929 |
3,595,011 |
| Thompson Peter A. | Director |
Dec 18 '25 |
Sale |
44.49 |
100 |
4,449 |
3,595,886 |
| Fitzpatrick Jennifer | Chief Legal Officer |
Dec 05 '25 |
Option Exercise |
6.11 |
10,250 |
62,628 |
10,250 |
| Fitzpatrick Jennifer | Chief Legal Officer |
Dec 05 '25 |
Sale |
40.52 |
10,250 |
415,330 |
0 |
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):